Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of SSGJ-613 for acute gouty arthritis in Chinese patients
CTR20233982Phase 3Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SSGJ-613 in acute gout flare, sponsored by 3S Guojian Pharmaceutical. Started Jan 2024; status: completed.
02
Drugs
SSGJ-613
03
Conditions
acute gout flare
Beyond the preview
Go deeper on CTR20233982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233982.